PapersFlow Research Brief
Chronic Lymphocytic Leukemia Research
Research Guide
What is Chronic Lymphocytic Leukemia Research?
Chronic lymphocytic leukemia (CLL) research is the study of the biology, classification, and treatment of CLL, including its genetic drivers, clonal evolution, and therapeutic vulnerabilities.
The provided dataset contains 98,395 works associated with chronic lymphocytic leukemia research (growth over 5 years: N/A)."The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (2016) provides a widely cited framework for classifying lymphoid neoplasms, which includes entities relevant to CLL diagnosis and related disorders. Calin et al. (2002) reported that deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 are frequent in CLL in "Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia" (2002).
Research Sub-Topics
BCR-ABL Negative Chronic Lymphocytic Leukemia
This sub-topic investigates the pathogenesis, genetic landscape, and microenvironment interactions specific to BCR-ABL negative CLL distinct from myeloid leukemias. Researchers study B-cell receptor signaling and immune evasion mechanisms.
miR15 and miR16 in Chronic Lymphocytic Leukemia
This sub-topic explores the 13q14 deletion involving miR15/16 tumor suppressors, their regulation of BCL2, and prognostic significance in CLL. Researchers develop miRNA-based diagnostics and restoration therapies.
WHO Classification of Lymphoid Neoplasms CLL
This sub-topic addresses 2016 WHO updates on CLL morphology, immunophenotype, and small lymphocytic lymphoma distinctions. Researchers study cyclin D1-negative entities and monoclonal B-cell lymphocytosis progression.
Age-Related Clonal Hematopoiesis in CLL
This sub-topic examines CHIP/DH mutations (DNMT3A, TET2, ASXL1) coexistence with CLL and their impact on therapy response and survival. Researchers investigate clonal evolution and inflammation contributions.
Rituximab in CLL Therapy
This sub-topic covers rituximab combination regimens (FR, FCR) efficacy, MRD endpoints, and resistance mechanisms in CLL. Researchers compare chemoimmunotherapy versus novel agents like ibrutinib.
Why It Matters
CLL research directly informs how patients are classified, risk-stratified, and treated in practice, because clinical decisions depend on consistent disease definitions and on mechanistic targets that can be therapeutically exploited. "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (2016) matters clinically because it codifies consensus diagnostic categories used by hematopathologists and clinicians when distinguishing CLL from other lymphoid neoplasms that require different management. Mechanistic CLL biology also has translational consequences: Calin et al. (2002) identified frequent 13q14 involvement through miR15/miR16 deletions and down-regulation in "Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia" (2002), helping anchor a gene-regulatory model of leukemogenesis that supports biomarker and target discovery. Beyond individual markers, community-scale multi-omics and computational resources aim to connect molecular alterations to outcomes at cohort scale; for example, the CLL-map project reports integrated genomic, transcriptomic, epigenomic, and clinical analysis from over 1100 CLL patients (getzlab/CLLmap), and reproducible multi-omics workflows are distributed as code (Huber-group-EMBL/mofaCLL). These efforts are practically relevant because they enable reproducible analyses and hypothesis generation for therapy selection, resistance, and transformation risk using real patient-scale datasets.
Reading Guide
Where to Start
Start with "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (2016) because it establishes the diagnostic and entity framework that underpins cohort definitions, pathology criteria, and comparability across CLL studies.
Key Papers Explained
A practical entry point is to connect disease definition to mechanism: "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (2016) anchors how CLL is delineated among lymphoid neoplasms, while Calin et al. (2002) provide a canonical molecular lesion in "Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia" (2002). Jaiswal et al. (2014) broaden interpretation of somatic variation in blood with "Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes" (2014), which is relevant when analyzing sequencing data from typical (older) CLL cohorts. For translational context on how mechanistic targets can become therapies in hematologic malignancies, Druker et al. (2001) in "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia" (2001) and O’Brien et al. (2003) in "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia" (2003) illustrate the evidentiary arc from target to clinical benefit, even though they are CML rather than CLL.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
For advanced work, pair the canonical CLL lesion and classification framework with patient-scale integrative modeling using shared code and data resources. The CLL-map project (getzlab/CLLmap) explicitly integrates genomic, transcriptomic, epigenomic, and clinical data from over 1100 CLL patients, enabling outcome-linked molecular mapping and replication. Reproducible pipelines (Huber-group-EMBL/mofaCLL) and lymphoma genomics resources (morinlab/LLMPP) support multi-cohort analysis, method benchmarking, and harmonized feature extraction for studies focused on heterogeneity, resistance, and transformation.
Papers at a Glance
In the News
FDA Oncology Update January 2026: New Horizons in ...
* Sevabertinib and zoldonrasib received breakthrough therapy designations for specific NSCLC mutations, highlighting advancements in targeted lung cancer treatments.
Blood Cancer United, formerly The Leukemia & Lymphoma ...
United provided early and ongoing support for some of the biggest cancer breakthroughs, including imatinib (Gleevec), rituximab (Rituxan), CAR T-cell immunotherapy, and most recently, menin inhibit...
First-line treatment for CLL in the era of targeted therapy
In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted...
A Combination Treatment May Help Cut Lifelong Ibrutinib ...
# A Combination Treatment May Help Cut Lifelong Ibrutinib for Chronic Lymphocytic Leukemia November 6, 2025
The Leukemia Research Foundation announces 2025 ...
The Leukemia Research Foundation’s competitive, peer-reviewed program funds innovative projects from early-career investigators who propose research that can lead to scientific breakthroughs. This ...
Code & Tools
## Repository files navigation # The CLL-map project code repository ### The project assembled and analyzed genomic, transcriptomic, epigenomic a...
## Repository files navigation # Lymphoma/Leukemia Molecular Profiling Project This is the landing page for the growing set of resources for l...
This package contains the R code implementing the computational analysis steps, in the form of Rmarkdown documents, that enable readers to reproduc...
## Repository files navigation # Molecular map of chronic lymphocytic leukemia and its impact on outcome ## Abstract
This repository contains code and data accompanying the study "Detection of early seeding of Richter transformation in chronic lymphocytic leukemia...
Recent Preprints
Research articles | Leukemia
### Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction * Marianne Ayoub * Casilda Hitier * Santos A. Sus...
First-line treatment for CLL in the era of targeted therapy
In the decade since FDA approval of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted...
Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL - PubMed
Over the past decade, treatment recommendations for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have shifted from traditional chemoimmunotherapy to targeted...
Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib
Terms such as*GLOW*,*CAPTIVATE*, and*AMPLIFY*have become increasingly familiar to hematologists involved in the management of chronic lymphocytic leukemia (CLL). These trials, all exploring time-li...
Chronic lymphocytic leukemia specificity analyses unveil bacterial lipopolysaccharides as the cognate ligands of established stereotyped BCR subsets
We thus describe a novel “immunological” M-CLL subset that specifically binds to a variety of lipopolysaccharides (LPS) derived from common gram-negative bacteria. Together, the four ERIC CLL stere...
Latest Developments
Recent developments in CLL research as of February 2026 include the approval of pirtobrutinib, a noncovalent BTK inhibitor, for CLL management (unapproved date, but supported by multiple sources from late 2025), and new data on time-limited, targeted therapies such as ibrutinib–venetoclax and zanubrutinib, with ongoing clinical trials exploring fixed-duration treatments and MRD-driven approaches (NEJM, Nature, Blood Cancer Journal).
Sources
Frequently Asked Questions
What is a widely used classification reference that CLL researchers cite when defining lymphoid neoplasm entities relevant to CLL?
"The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (2016) is a consensus revision that updates entities and diagnostic criteria across lymphoid neoplasms. It is routinely used as a shared reference point when studies specify inclusion criteria and when clinicians align research cohorts to diagnostic categories.
How did microRNA biology become connected to CLL pathogenesis in the highly cited literature?
Calin et al. (2002) reported frequent deletions and down-regulation of miR15 and miR16 at 13q14 in CLL in "Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia" (2002). This linked noncoding RNA dysregulation to a recurrent CLL genomic locus and provided a mechanistic foothold for studying gene-regulatory disruption in CLL.
Which paper in the provided list is most directly CLL-specific among the top-cited items?
"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia" (2002) is explicitly focused on CLL and is one of the most-cited CLL-relevant papers in the provided list. It centers on a recurrent locus (13q14) and microRNA changes in CLL rather than on other hematologic malignancies or non-CLL diseases.
How do researchers study clonal origins relevant to leukemia risk in aging, and why does that matter for CLL research cohorts?
Jaiswal et al. (2014) described age-related clonal hematopoiesis and its association with adverse outcomes in "Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes" (2014). This is relevant to CLL research because age-related clonal processes can complicate interpretation of blood-based genomic data and may influence how cohorts are stratified when studying somatic variation.
Which open, reproducible computational resources are explicitly provided for large-scale CLL molecular analysis?
The CLL-map project reports analysis of genomic, transcriptomic, epigenomic, and clinical data from over 1100 CLL patients (getzlab/CLLmap). Additional shared resources include the Lymphoma/Leukemia Molecular Profiling Project repository (morinlab/LLMPP) and reproducible multi-omics analysis code distributed as mofaCLL (Huber-group-EMBL/mofaCLL).
Which highly cited papers in the list are not CLL-specific but are commonly referenced as methodological or conceptual precedents in hematologic oncology?
"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia" (2001) and "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia" (2003) are CML-focused but are often cited as precedent for targeted therapy development in blood cancers. "CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma" (2002) is lymphoma-focused and is commonly referenced for anti-CD20 immunochemotherapy concepts that informed later B-cell malignancy trial design.
Open Research Questions
- ? Which specific downstream gene-regulatory programs are most consistently perturbed by miR15/miR16 loss at 13q14 across independent CLL cohorts, and which are causal versus secondary effects?
- ? How should CLL molecular studies distinguish age-related clonal hematopoiesis signals from CLL-derived somatic alterations when analyzing blood or marrow sequencing data in older cohorts?
- ? Which multi-omic feature sets (genomic, transcriptomic, epigenomic, clinical) best predict clinically meaningful outcomes when models are trained and validated across patient-scale resources such as the >1100-patient CLL-map dataset?
- ? How can standardized disease definitions from "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" (2016) be operationalized in computational pipelines to reduce cross-study heterogeneity in CLL cohort construction?
- ? Which molecular patterns in longitudinal multi-omics data most reliably precede clinically apparent progression or transformation events, and how early can they be detected in real-world datasets?
Recent Trends
In the provided materials, recent emphasis is on scaling from single-lesion insights to cohort-scale, multi-omics integration and reproducible analysis.
The CLL-map resource explicitly reports integrated genomic, transcriptomic, epigenomic, and clinical analysis from over 1100 CLL patients (getzlab/CLLmap), reflecting a move toward outcome-linked molecular atlases rather than isolated marker studies.
In parallel, reproducible computational workflows are being distributed as code (Huber-group-EMBL/mofaCLL) and broader lymphoma/leukemia genomics resources are maintained (morinlab/LLMPP), reinforcing a trend toward transparent, reusable pipelines for cross-study validation.
At the conceptual level, the continued high citation of "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" indicates sustained reliance on standardized diagnostic categories, while Calin et al. (2002) remains a central molecular reference for 13q14/miR15–miR16 biology in CLL.
2016Research Chronic Lymphocytic Leukemia Research with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Chronic Lymphocytic Leukemia Research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.